Surgical Management of Gastrointestinal Stromal Tumors (GISTs)

Primary Surgical Approach

The standard treatment for localized GISTs amenable to wedge resection is complete surgical excision with negative margins via wedge resection, prioritizing functional preservation while achieving R0 resection, as recommended by the National Comprehensive Cancer Network 1, 2
Complete macroscopic and microscopic resection (R0) with negative margins is the primary goal of GIST surgery, according to the European Society for Medical Oncology 1, 2
Functional preservation through wedge resection when anatomically feasible is a key principle of GIST surgery, as stated by the American Joint Committee on Cancer 1, 2

Avoidance of tumor rupture and pseudocapsule injury is crucial, as rupture dramatically increases peritoneal recurrence risk and automatically places patients in high-risk category, as noted by the National Institute of Health 3
No lymph node dissection is required for standard GISTs, as lymphatic spread is extremely rare, except for SDH-mutated GISTs, which may warrant pickup dissection of enlarged nodes, according to the American College of Surgeons 1, 2, 4
Avoid direct tumor handling with forceps; use plastic bags for specimen removal to prevent tumor seeding, as recommended by the Society of Surgical Oncology 1, 2, 3

Laparoscopic wedge resection is the preferred approach for gastric GISTs ≤5 cm, offering reduced morbidity with equivalent oncological outcomes, as stated by the American Society of Clinical Oncology 1, 2
GISTs >5 cm or non-gastric locations have limited data, and the laparoscopic approach carries higher rupture risk and is not routinely recommended, according to the European Association for Endoscopic Surgery 1

Gastric/duodenal nodules <2 cm can be assessed with endoscopic ultrasound and followed up, reserving excision for growing or symptomatic lesions, as recommended by the American Gastroenterological Association 5
Rectal nodules should be biopsied or excised regardless of size, as rectal GISTs carry higher progression risk and worse prognosis, according to the National Comprehensive Cancer Network 5
Standard approach for medium GISTs (2-5 cm) is biopsy/excision due to higher progression risk, as stated by the European Society for Medical Oncology 5
Large GISTs (>5 cm) should be resected surgically, except for definitively benign tumors, as recommended by the American College of Surgeons 1

Risk stratification determines adjuvant therapy need, based on tumor size, mitotic index, tumor location, and tumor rupture, as stated by the National Comprehensive Cancer Network 1
High-risk GISTs require 3 years of adjuvant imatinib 400 mg daily, or 800 mg for KIT exon 9 mutations, according to the European Society for Medical Oncology 2
Tumor rupture/perforation mandates adjuvant imatinib due to very high peritoneal recurrence risk, with consideration for lifelong treatment, as recommended by the American Society of Clinical Oncology 3

Mutational analysis for KIT and PDGFRA should be standard practice for all GISTs, except for <2 cm non-rectal GISTs unlikely to need medical treatment, as stated by the National Institute of Health 5
Predictive value of mutational analysis determines sensitivity to targeted therapy, and prognostic value informs risk assessment, according to the American College of Medical Genetics 5
Mutational analysis should be centralized in laboratories with expertise and quality assurance, as recommended by the College of American Pathologists 5